55676-90-9

Basic information

• Product Name: Benzene, 1-chloro-2-(chloromethyl)-3-methyl-
• CAS NO: 55676-90-9
• Molecular Formula: C8H8Cl2
• Molecular Weight: 175.058
• Mol File: 55676-90-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzene, 1-chloro-2-(chloromethyl)-3-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-chloro-2-(chloromethyl)-3-methyl-(55676-90-9)
• EPA Substance Registry System: Benzene, 1-chloro-2-(chloromethyl)-3-methyl-(55676-90-9)

Safety Data

• Hazardous Substances Data: 55676-90-9(Hazardous Substances Data)

Upstream product

• 95-47-6 o-xylene 
• 87-63-8 2-chloro-6-methylaniline 
• 1194-64-5 2-chloro-6-methylbenzaldehyde 
• 77206-89-4 (2-chloro-6-methylphenyl)methanol 

Downstream Products

• 95-47-6 o-xylene 
• 58529-99-0 5-chloro-6,2',5'-trimethyl-diphenylmethane 
• 55676-82-9 2-benzyl-6-chlorotoluene 
• 76574-82-8 6-(2-chloro-6-methylphenyl)-2-methylpyrido[2,3-d]-pyrimidin-7-amine 
• 76574-62-4 6-(2-Chloro-6-methyl-phenyl)-pyrido[2,3-d]pyrimidin-7-ylamine 
• 76574-40-8 2-(2-chloro-6-methyl-phenyl)acetonitrile 

Relevant articles and documents

DIFLUOROMETHYLENE COMPOUND

The present invention relates to a compound having an URAT1 inhibitory activity, and to an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound. More specifically, the present invention relates to a compound represented by the formula (I): wherein R1 is -Q1-A1 or the like; R2 is a hydrogen atom, a halogen atom, a lower alkyl group or the like; W1, W2, W3 and W4 are each independently a nitrogen atom or a methine group optionally having substituents, or the like; X and Y are each a single bond, an oxygen atom or the like; Z is a hydroxyl group or COOR3 or the like.

Antihypertensive Activity of 6-Arylpyridopyrimidin-7-amine Derivatives

A series of 51 6-arylpyridopyrimidin-7-amine derivatives was prepared and evaluated for antihypertensive activity in the conscious spontaneously hypertensive rat.A number of these compounds, notably 6-(2,6-dichlorophenyl)-2-methylpyridopyrimidin-7-amine (36), lowered blood pressure in these rats in a gradual and sustained manner to normotensive levels at oral doses of 10-50 mg/kg.Normalized blood pressure levels could then be maintained by single daily oral doses.The effect of structural variation in the 6-aryl group and in the 2 and 4 positions of the pyridopyrimidine ring on activity is reported and discussed.